Holen Sie sich die Stockscreener-App
38.02
2.34%
-0.91
Schlusskurs vom Vortag:
$38.93
Offen:
$39.1
24-Stunden-Volumen:
1.94M
Relative Volume:
1.36
Marktkapitalisierung:
$3.68B
Einnahmen:
$7.50M
Nettoeinkommen (Verlust:
$-383.17M
KGV:
-8.0811
EPS:
-4.7048
Netto-Cashflow:
$-307.84M
1W Leistung:
+2.92%
1M Leistung:
-36.80%
6M Leistung:
-33.12%
1J Leistung:
-3.01%
1-Tages-Spanne:
$37.26
$39.10
1-Wochen-Bereich:
$36.10
$39.92
52-Wochen-Spanne:
$36.07
$72.66
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
38.02 | 3.58B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals (XENE) Shares Rise After CEO and CFO Buy $1.7M in Stock - GuruFocus
Xenon rises on insider buys from CEO and CFO (XENE:NASDAQ) - Seeking Alpha
Why is Xenon Pharmaceuticals stock rallying today? - Investing.com India
Xenon Pharmaceuticals (XENE) CFO Thomas Kelly Buys 15,000 Shares in Open-Market Purchase - GuruFocus
Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month - TradingView
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says - marketscreener.com
At $37.316 each, CFO Kelly buys 15,000 Xenon Pharmaceuticals (XENE) shares. - Stock Titan
Xenon Pharmaceuticals President & CEO Purchased Shares Worth Over $1.1M - TradingView
At $37.38 a share, Xenon Pharmaceuticals (XENE) CEO Ian Mortimer buys company stock. - Stock Titan
Gross margin % of Xenon Pharmaceuticals Inc. – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.70 after FDA filing - AD HOC NEWS
Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc. Balance Sheet – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.30 after trial pause - AD HOC NEWS
Xenon Pharmaceuticals Inc. (XENE) Interactive Stock ChartYahoo Finance - Yahoo! Finance Canada
Ian Mortimer Receives the 2026 Bloom Burton Award - Nasdaq
Defence Therapeutics appoints Sherry Aulin to B... - Pluang
Jefferies cuts Xenon Pharmaceuticals stock price target on trial pause By Investing.com - Investing.com Canada
Xenon Pharmaceuticals Inc. (XENE) Latest Stock News & HeadlinesYahoo Finance - ca.finance.yahoo.com
(XENE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Xenon Pharmaceuticals Inc. (XENE) stock price, news, quote and history - Yahoo Finance UK
XENE Investor Alert: Levi & Korsinsky Investigates Xenon Pharmaceuticals Inc. (XENE) For Potential Securities Fraud - ACCESS Newswire
Levi & Korsinsky Announces Investigation of Securities Claims Against Xenon Pharmaceuticals Inc. (XENE) - ACCESS Newswire
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law - Business Wire
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback? - Insider Monkey
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) - Block Island Times
Xenon Pharmaceuticals stock falls 30.69 percent as trial pause hits - AD HOC NEWS
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate (XENE) - Seeking Alpha
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors - GlobeNewswire
Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures - NeurologyLive
Xenon will present a drug being developed for epilepsy and two types of depression - Stock Titan
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit - GlobeNewswire
Xenon Pharmaceuticals Craters 30%: Reading the Charts After the Depression Trial Pause - MEXC
Company News for Sep 21, 2026 - Yahoo Finance
Xenon shares slide more than 30% as company pauses psychiatry trial enrollment - thepharmaletter.com
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment - TIKR.com
Xenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's Why - webull.com
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Envista Holdings (NVST) - The Globe and Mail
XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial - Yahoo Finance
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain. - Barron's
XENE Stock Drops 30% on Phase 3 Trial Halt; Price-to-Sales Ratio Signals Market Skepticism - GuruFocus
Xenon Halts Enrollment in Depression Trials After Psychosis Reports - finance.biggo.com
Xenon downgraded at Deutsche Bank on trial pause (XENE:NASDAQ) - Seeking Alpha
Xenon stock plunges as B.C. drug developer pauses enrolment in depression study - The Globe and Mail
Xenon: The Psychiatry Pause Matters More Than You Think (Rating Downgrade) (NASDAQ:XENE) - Seeking Alpha
Dow Falls Over 200 Points; Xenon Pharmaceuticals Shares Plunge - Benzinga
Xenon: FOS read-across in MDD, BD hitches with Kv7? - BioWorld News
Xenon Pharmaceuticals Faces Setback Amid Clinical Study Pause - GuruFocus
XENE Maintains Outperform Rating -- Price Target Lowered to $70 - GuruFocus
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause - Yahoo Finance
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xenon Pharmaceuticals Inc-Aktie (XENE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT & CEO |
Sep 30 '26 |
Buy |
37.38 |
30,000 |
1,121,400 |
49,923 |
| Svoronos Dawn | Director |
Sep 01 '26 |
Option Exercise |
8.15 |
5,144 |
41,924 |
31,373 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer |
Aug 28 '26 |
Sale |
60.25 |
7,068 |
425,829 |
2 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):